Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2024
Molnupiravir for the treatment of patients with COVID-19 infection
26 November 2024 - NICE has published further draft guidance on the use of molnupiravir (Lagevrio) in the NHS in ...
Posted by Michael Wonder on 18 Oct 2024
PHARMAC seeking bids from suppliers for COVID-19 vaccines
17 October 2024 - PHARMAC is seeking bids from pharmaceutical suppliers of COVID-19 vaccines. ...
Posted by Michael Wonder on 21 Sep 2024
New COVID-19 vaccine by Moderna approved by Health Canada
17 September 2024 - Health Canada has approved an updated version of Moderna’s COVID-19 vaccine, a decision that means some ...
Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...
Posted by Michael Wonder on 05 May 2024
PHARMAC and Health NZ weigh up future of COVID-19 vaccines and treatments
3 May 2024 - PHARMAC and Health NZ are weighing up the future direction of COVID-19 vaccinations and treatments in ...
Posted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
Posted by Michael Wonder on 22 Feb 2024
COVID-19 vaccine available in March
22 February 2024 - Joint media release with Health New Zealand. ...
Posted by Michael Wonder on 23 Jan 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
Posted by Michael Wonder on 22 Jan 2024
NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19
18 January 2024 - Draft guidance for public consultation has been published by NICE. ...
Posted by Michael Wonder on 14 Jan 2024
1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid
11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...
Posted by Michael Wonder on 21 Dec 2023
Future supply of new COVID-19 vaccines confirmed
20 December 2023 - A vaccine to combat the newer strains of COVID-19 has been approved and will be available ...
Posted by Michael Wonder on 07 Dec 2023
Evolving our approach to COVID-19 vaccines and treatments
6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...
Posted by Michael Wonder on 20 Sep 2023
Access to COVID-19 anti-viral treatments widened for more people at risk
20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...
Posted by Michael Wonder on 18 Sep 2023
COVID-19 vaccine contract summary
18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...
Posted by Michael Wonder on 16 Aug 2023
PHARMAC calls for applications from the suppliers of vaccines that protect against COVID-19
16 August 2023 - PHARMAC is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and ...